Canakinumab is a monoclonal antibody that specifically targets interleukin-1 beta (IL-1β), a pro-inflammatory cytokine involved in various inflammatory diseases. It is primarily used in the treatment of conditions such as systemic juvenile idiopathic arthritis, adult-onset Still's disease, and certain types of cryopyrin-associated periodic syndromes. As a human IgG1κ antibody, Canakinumab is designed to inhibit the activity of IL-1β, thereby reducing inflammation and associated symptoms. The drug is administered via subcutaneous injection and has a relatively long half-life, allowing for less frequent dosing. Its mechanism of action involves binding to IL-1β, preventing it from interacting with its receptor, which is crucial for mediating inflammatory responses. Canakinumab has been studied for its efficacy and safety profile in various clinical trials, demonstrating significant benefits in reducing disease activity and improving quality of life for patients with chronic inflammatory conditions. As with any therapeutic agent, potential side effects may include increased risk of infections and other immune-related reactions.

Canakinumab

914613-48-2: Ilaris, Canakinumab, ACZ 885

Canakinumab: Human IL-1β antibody, anti-inflammatory, treats gout & coronary disease, IC50 of 43.6 pM (human), 40.8 pM (monkey).

Canakinumab is a human monoclonal antibody that binds to interleukin-1β and inhibits its biological activity, which is involved in the pathogenesis of various autoimmune diseases. Canakinumab has been shown to be effective in the treatment of chronic arthritis, long-term efficacy, and toxicological studies. The compound also reduces the activity index in patients with congestive heart failure or bowel disease. Canakinumab does not inhibit cyclooxygenase enzymes and does not have anti-inflammatory properties.

CAS 914613-48-2: Canakinumab

Canakinumab

Ref: TM-T73695

Canakinumab - in PBS buffer approx. 15mg/ml

Ref: 3D-BC176794